The SIBERIA study demonstrated a clear advantage of CGuard stent implantation over the existing classical stent when using a distal anti-embolic device. At the same time, there is no Level 1 evidence for a difference between the proximal and distal anti-embolic device for the CGuard stent.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
366
Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™
Embolic Protection System for Carotid Artery Revascularization ( proximal - occlusion) + stent CGuardTM™
E. Meshalkin National Medical Research Center
Novosibirsk, Russia
RECRUITINGdetermination of ischemic lesions
Postprocedural acute ischemic lesions (MRI)
Time frame: 24-48 hours
MACCE
Death, stroke, and MI
Time frame: Intraoperatively, and within 48 hours.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.